These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preparation of Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436 [TBL] [Abstract][Full Text] [Related]
3. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278 [TBL] [Abstract][Full Text] [Related]
4. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032 [TBL] [Abstract][Full Text] [Related]
5. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676 [No Abstract] [Full Text] [Related]
7. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Theranostics With Ahmadzadehfar H; Seifert R; Afshar-Oromieh A; Kratochwil C; Rahbar K Semin Nucl Med; 2024 Jul; 54(4):581-590. PubMed ID: 38570288 [TBL] [Abstract][Full Text] [Related]
12. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
13. Real-World Experience with Moradi Tuchayi A; Yadav S; Jiang F; Kim ST; Saelee RK; Morley A; Juarez R; Lawhn-Heath C; Wang Y; de Kouchkovsky I; Hope TA J Nucl Med; 2024 May; 65(5):735-739. PubMed ID: 38485274 [TBL] [Abstract][Full Text] [Related]
14. [ Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180 [TBL] [Abstract][Full Text] [Related]
15. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [ Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600 [TBL] [Abstract][Full Text] [Related]
16. Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical Tishchenko VK; Vlasova OP; Lebedeva AA; Fedorova AV; Pankratov AA; Morozova NB; Kuzenkova KA; Stepchenkova ED; Shegai PV; Ivanov SA; Kaprin AD Bull Exp Biol Med; 2023 Dec; 176(2):224-226. PubMed ID: 38191882 [TBL] [Abstract][Full Text] [Related]
17. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
19. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside? Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008 [TBL] [Abstract][Full Text] [Related]
20. Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma. More S; Naiker T; Jacobs N; Oompie F; Prasad V Clin Nucl Med; 2023 May; 48(5):e217-e218. PubMed ID: 36881610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]